0000904454-20-000661.txt : 20201016
0000904454-20-000661.hdr.sgml : 20201016
20201016161000
ACCESSION NUMBER: 0000904454-20-000661
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201014
FILED AS OF DATE: 20201016
DATE AS OF CHANGE: 20201016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kapusta Matthew C
CENTRAL INDEX KEY: 0001536290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36294
FILM NUMBER: 201244080
MAIL ADDRESS:
STREET 1: 7358 MCVAY ROAD
CITY: GERMANTOWN
STATE: TN
ZIP: 38138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: uniQure N.V.
CENTRAL INDEX KEY: 0001590560
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
BUSINESS PHONE: 1-339-970-7000
MAIL ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
FORMER COMPANY:
FORMER CONFORMED NAME: uniQure B.V.
DATE OF NAME CHANGE: 20131030
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-10-14
0001590560
uniQure N.V.
QURE
0001536290
Kapusta Matthew C
C/O UNIQURE N.V.
PAASHEUVELWEG 25A
AMSTERDAM
P7
11058BP
NETHERLANDS
1
1
0
0
CEO, CFO, Managing Director
Ordinary Shares
2020-10-14
4
S
0
4950
35.82
D
280864
D
Ordinary Shares
2020-10-14
4
S
0
300
36.49
D
280564
D
The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.35 to $36.34. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.38 to $36.58. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Christian Klemt, Attorney-in-Fact
2020-10-16